Table 1 Patient clinical characteristics.

From: Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

Pt ID	Group	Trial	Age	TN	Stage	Histological type	Response to Th	Breast RT size (mm)	Number of involved LNs post-NAT	Recurrence site	TTR, from surgery (months)	Survival from surgery until death or the end of follow-up (months)
65	A	PTMB	55	T2N0	IIA	NST	Non-pCR	30	0	Lungs, bone	6	8
49	A	PTMB	55	T3N1	IIIA	NST	Non-pCR	70	9	Liver	3	8
9	A	PTMB	44	T2N0	IIA	NST	Non-pCR	50	1	Brain	5	6
52	A	PTMB	67	T2N0	IIA	NST	Non-pCR	80	6	Breast, lungs	5	7
46	A	CTX	46	T2N0	IIA	NST	Non-pCR	45	0	Lungs	12	17
71	A	PTMB	42	T2N0	IIA	NST	Non-pCR	18	2	Lungs, liver	9	15
38	B	PTMB	50	T3N0	IIB	NST	pCR	0	0	Solitary brain metastasis	40	60
10	B	PTMB	73	T3N2	IIIA	Apocrine	Non-pCR	60	9	Lungs	34	60
33	B	CTX	64	T3N0	IIB	NST	Non-pCR	20	0	Lungs	46	60
44	B	CTX	50	T2N1	IIB	NST	Non-pCR	55		Lungs	17	60
72	B	PTMB	65	T2N0	IIA	NST	pCR	0	0	Brain	23	24
73	B	PTMB	57	T2N0	IIA	NST	Non-pCR	5	1	Lungs, liver	17	26
32	C	PTMB	35	T3N1	IIIA	NST	Non-pCR	45	2	None	NA	60
60	C	CTX	67	T3N1	IIIA	NST	Non-pCR	60	0	None	NA	60
54	C	PTMB	29	T2N0	IIA	NST	Non-pCR	55	1	None	NA	60
23	C	CTX	54	T3N1	IIIA	NST	Non-pCR	50	0	None	NA	60
50	C	PTMB	42	T2N0	IIA	NST	Non-pCR	45	0	None	NA	60
21	C	CTX	61	T2N1	IIB	NST	Non-pCR	35	0	None	NA	60
11	C	PTMB	42	T2N1	IIB	NST	Non-pCR	35	2	None	NA	60
48	C	PTMB	53	T3N2	IIIA	NST	Non-pCR	35	0	None	NA	60
68	D	PTMB	62	T2N1	IIB	NST	Non-pCR	30	1	None	NA	60
34	D	PTMB	44	T2N0	IIA	NST	Non-pCR	25	0	None	NA	60
45	D	CTX	42	T2N0	IIA	NST	Non-pCR	25	0	None	NA	60
56	D	CTX	54	T2N0	IIA	NST	Non-pCR	25	0	None	NA	60
13	E	PTMB	50	T2N0	IIA	NST	Non-pCR	20	0	None	NA	60
69	E	PTMB	40	T3N0	IIB	NST	Non-pCR	20	0	None	NA	60
67	E	PTMB	54	T2N0	IIA	NST	Non-pCR	20	1	Breast	NA	60
64	E	CTX	37	T2N1	IIB	NST	Non-pCR	20	1	None	NA	60
40	E	CTX	59	T2N0	IIA	NST	Non-pCR	20	0	None	NA	60
57	E	CTX	53	T3N0	IIB	NST	Non-pCR	16	0	None	NA	60
70	E	CTX	28	T2N1	IIB	NST	Non-pCR	15	4	None	NA	60
30	E	CTX	47	T3N0	IIB	NST	Non-pCR	12	4	None	NA	60
28	E	CTX	34	T2N1	IIB	NST	Non-pCR	10	0	None	NA	60
36	E	PTMB	39	T3N0	IIB	NST	Non-pCR	9	0	None	NA	60
35	E	CTX	38	T2N2	IIIA	NST	Non-pCR	7	3	None	NA	60
19	E	CTX	52	T3N0	IIB	NST	Non-pCR	2	3	None	NA	60
74	E	PTMB	35	T2N0	IIA	NST	Non-pCR	6	0	None	NA	60
75	E	CTX	60	T2N0	IIA	NST	Non-pCR	3	0	None	NA	60
76	E	PTMB	48	T2N1	IIB	NST	Non-pCR	2	2	None	NA	60
84	E	PTMB	43	T3N1	IIIA	NST	Non-pCR	7	2	None	NA	60
85	E	CTX	63	T2N1	IIB	NST	Non-pCR	12	0	None	NA	60
86	E	CTX	46	T2N1	IIB	NST	Non-pCR	4	0	None	NA	60
26	F	PTMB	27	T2N0	IIA	NST	pCR	0	0	None	NA	60
47	F	PTMB	52	T2N1	IIB	NST	pCR	0	0	None	NA	60
16	F	CTX	64	T2N0	IIA	NST	pCR	0	0	None	NA	60
15	F	PTMB	43	T2N0	IIA	NST	pCR	0	0	None	NA	60
22	F	CTX	54	T2N0	IIA	NST	pCR	0	0	None	NA	60
27	F	PTMB	40	T2N0	IIA	NST	pCR	0	0	None	NA	60
39	F	CTX	48	T2N0	IIA	NST	pCR	0	0	None	NA	60
41	F	PTMB	30	T2N0	IIA	NST	pCR	0	0	None	NA	60
3	F	PTMB	41	T2N0	IIA	NST	pCR	0	0	None	NA	60
4	F	PTMB	31	T2N1	IIB	NST	pCR	0	0	None	NA	60
6	F	PTMB	65	T2N0	IIA	NST	pCR	0	0	None	NA	60
8	F	PTMB	36	T2N1	IIB	NST	pCR	0	0	None	NA	60
43	F	CTX	47	T2N0	IIA	NST	pCR	0	0	None	NA	60
77	F	PTMB	49	T2N1	IIB	NST	pCR	0	0	None	NA	60
78	F	PTMB	56	T3N0	IIB	NST	pCR	0	0	None	NA	60
79	F	CTX	61	T2N0	IIA	NST	pCR	0	0	None	NA	60
80	F	CTX	33	T2N1	IIB	NST	pCR	0	0	None	NA	60
81	F	PTMB	50	T2N0	IIA	NST	pCR	0	0	None	NA	60
82	F	PTMB	65	T2N1	IIA	NST	pCR	0	0	None	NA	60
83	F	PTMB	42	T2N0	IIA	NST	pCR	0	0	None	NA	60

Legend: RT residual tumor, PTMB panitumumab trial: panitumumab (Vectibix^®), 9 mg/kg intravenous cycles combined with FEC × 4 (500/100/500 mg/m²), followed by docetaxel × 4 (100 mg/m²); CTX, cetuximab trial: 18 intravenous weekly infusions (Day1/8/15) of cetuximab (Erbitux^®) (first infusion: 400 mg/m²; subsequently: 250 mg/m²) combined with docetaxel (100 mg/m²) on Day1 q3 weekly for six cycles; NST non-special type, LNs lymph nodes, NAT neoadjuvant treatment, TTR time to recurrence, pre, a sample taken before neoadjuvant treatment; post, a sample is taken after neoadjuvant treatment; pCR pathological complete response, NA not applicable.

Back to article page

Table 1 Patient clinical characteristics.

Search

Quick links